Most-Downgraded StocksMost-DowngradedNASDAQ:ACCD Accolade (ACCD) Stock Price, News & Analysis $4.08 +0.23 (+5.97%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.92▼$4.1150-Day Range$3.40▼$7.6852-Week Range$3.35▼$15.36Volume1.48 million shsAverage Volume1.03 million shsMarket Capitalization$326.44 millionP/E RatioN/ADividend YieldN/APrice Target$11.65 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Accolade alerts: Email Address Accolade MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside185.6% Upside$11.65 Price TargetShort InterestHealthy3.90% of Shares Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment0.29Based on 2 Articles This WeekInsider TradingSelling Shares$102,466 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.17) to ($1.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.91 out of 5 starsBusiness Services Sector11th out of 317 stocksBusiness Services, Not Elsewhere Classified Industry6th out of 93 stocks 4.4 Analyst's Opinion Consensus RatingAccolade has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAccolade has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Accolade's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.90% of the outstanding shares of Accolade have been sold short.Short Interest Ratio / Days to CoverAccolade has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Accolade has recently decreased by 17.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAccolade does not currently pay a dividend.Dividend GrowthAccolade does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccolade has received a 76.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private oncologist's appointments", "Private neurologist's appointments", "Private general practice doctor's diagnostic online appointments", "Private cardiologist's online appointments", and "Private gynaecologist's online appointments" products. See details.Environmental SustainabilityThe Environmental Impact score for Accolade is -0.89. Previous Next 2.4 News and Social Media Coverage News SentimentAccolade has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Accolade this week, compared to 3 articles on an average week.Search Interest7 people have searched for ACCD on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows7 people have added Accolade to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $102,466.00 in company stock.Percentage Held by InsidersOnly 8.20% of the stock of Accolade is held by insiders.Percentage Held by Institutions84.99% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Accolade's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Accolade are expected to grow in the coming year, from ($1.17) to ($1.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accolade is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accolade is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAccolade has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Accolade's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Accolade Stock (NASDAQ:ACCD)Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.Read More ACCD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACCD Stock News HeadlinesJuly 19, 2024 | globenewswire.comAccolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 17, 2024 | reuters.comPernod Ricard to sell bulk of wine portfolio to Accolade Wine ownersJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 16, 2024 | americanbankingnews.comAccolade, Inc. (NASDAQ:ACCD) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 15, 2024 | businesswire.comAccolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 14, 2024 | globenewswire.comAccolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 9, 2024 | globenewswire.comAccolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJune 28, 2024 | barrons.comAccolade Stock Sinks After Earnings. The Case to Buy the Dip.July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 28, 2024 | seekingalpha.comAccolade: Mixed Guidance (Rating Downgrade)June 27, 2024 | investorplace.comACCD Stock Earnings: Accolade Beats EPS, Beats Revenue for Q1 2025June 27, 2024 | seekingalpha.comAccolade, Inc. 2025 Q1 - Results - Earnings Call PresentationJune 27, 2024 | globenewswire.comAccolade Announces Results for Fiscal First Quarter 2025June 12, 2024 | globenewswire.comAccolade to Announce Fiscal First Quarter 2025 Financial ResultsMay 29, 2024 | finance.yahoo.comAccolade To Present at William Blair Growth Stock ConferenceMay 21, 2024 | prnewswire.comAccolade Welcomes Noom to Trusted Partner EcosystemMay 10, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtApril 30, 2024 | finance.yahoo.comAccolade, Inc. (NASDAQ:ACCD) Q4 2024 Earnings Call TranscriptSee More Headlines Receive ACCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/27/2024Today7/26/2024Next Earnings (Estimated)10/02/2024Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Business services, not elsewhere classified Sub-IndustryBusiness Services Current SymbolNASDAQ:ACCD CUSIPN/A CIK1481646 Webaccolade.com Phone206-926-8100FaxN/AEmployees2,400Year FoundedN/APrice Target and Rating Average Stock Price Target$11.65 High Stock Price Target$18.00 Low Stock Price Target$5.50 Potential Upside/Downside+192.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-99,810,000.00 Net Margins-20.62% Pretax Margin-20.28% Return on Equity-20.30% Return on Assets-11.14% Debt Debt-to-Equity Ratio0.48 Current Ratio2.80 Quick Ratio2.80 Sales & Book Value Annual Sales$414.29 million Price / Sales0.77 Cash FlowN/A Price / Cash FlowN/A Book Value$5.44 per share Price / Book0.73Miscellaneous Outstanding Shares80,010,000Free Float73,447,000Market Cap$318.44 million OptionableOptionable Beta2.00 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Rajeev Singh (Age 56)Chairman of the Board & CEO Comp: $778.5kMr. Robert Cavanaugh (Age 55)President Comp: $582.63kMr. Stephen H. Barnes CPA (Age 52)CFO & Treasurer Comp: $557.5kMs. Kristen BruzekSenior Vice President of OperationsMr. Colin McHugh (Age 45)Chief Accounting Officer Mr. Todd FriedmanSenior Vice President of Investor RelationsMr. Richard Eskew (Age 49)Executive VP, General Counsel, CCO & Secretary Ms. Kelsi McDonald HarrisChief People Officer & Senior Vice PresidentMr. Drew GarnerExecutive Vice President of EngineeringDr. Shantanu Nundy M.B.A.M.D., Executive VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory BoardMore ExecutivesKey CompetitorsEmeraldNYSE:EEXMontrose Environmental GroupNYSE:MEGGlobal Blue GroupNYSE:GBRepayNASDAQ:RPAYMediaAlphaNYSE:MAXView All CompetitorsInsiders & InstitutionsARK Investment Management LLCBought 28,405 shares on 7/26/2024Ownership: 7.051%Bank of New York Mellon CorpSold 150,686 shares on 7/26/2024Ownership: 0.348%Sumitomo Mitsui Trust Holdings Inc.Bought 314,371 shares on 7/19/2024Ownership: 2.515%Rajeev SinghSold 383 sharesTotal: $1,478.38 ($3.86/share)Stephen H BarnesSold 122 sharesTotal: $470.92 ($3.86/share)View All Insider TransactionsView All Institutional Transactions ACCD Stock Analysis - Frequently Asked Questions How have ACCD shares performed this year? Accolade's stock was trading at $12.01 at the start of the year. Since then, ACCD stock has decreased by 66.0% and is now trading at $4.08. View the best growth stocks for 2024 here. How were Accolade's earnings last quarter? Accolade, Inc. (NASDAQ:ACCD) released its quarterly earnings results on Thursday, June, 27th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.13. The firm's revenue for the quarter was up 18.6% compared to the same quarter last year. What is Rajeev Singh's approval rating as Accolade's CEO? 152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees. When did Accolade IPO? Accolade (ACCD) raised $176 million in an IPO on Thursday, July 2nd 2020. The company issued 8,800,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers. Who are Accolade's major shareholders? Accolade's top institutional shareholders include ARK Investment Management LLC (7.05%), Sumitomo Mitsui Trust Holdings Inc. (2.51%), Bank of New York Mellon Corp (0.35%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Stephen H Barnes, Robert N Cavanaugh, Michael W Hilton, Colin Mchugh and Richard Eskew. View institutional ownership trends. How do I buy shares of Accolade? Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Accolade own? Based on aggregate information from My MarketBeat watchlists, some other companies that Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD) and Procter & Gamble (PG). This page (NASDAQ:ACCD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accolade, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Accolade With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
